Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction-associated Steatotic Liver Disease in Clinical Practice.


Por: Olveira A, Crespo J, Ibañez-Samaniego L, Gallego-Durán R, Calleja JL, Aller R, Soria A, Gómez-Camarero J, Martín-Mateos R, Benlloch S, Pericàs JM, Morillas RM, Bernal-Monterde V, Diago M, Turnes J, Poca M, Lo Iacono O, Maya-Miles D, Escudero D, Andrade RJ, Rosales JM, Jorquera F, Fernández-Rodríguez C, Hernández-Guerra M, Romero-Gómez M and Ampuero J

Publicada: 1 abr 2026 Ahead of Print: 2 sep 2025
Resumen:
BACKGROUND & AIMS: Resmetirom is the first Food and Drug Administration-approved drug for metabolic dysfunction-associated liver disease (MASLD) in F2 and F3 patients with steatohepatitis. Noninvasive criteria have been proposed for initiating treatment; however, these have not been validated in clinical practice. We validated the proposed criteria and established new guidelines for initiating resmetirom treatment in clinical practice. METHODS: This was a cross-sectional study of 1281 MASLD patients from the HEPAmet registry with biopsy, comorbidity assessment, analytical profile, and elastography. Identification of MASLD with F2 and F3 was the main endpoint. A comprehensive review of international guidelines and expert consensus up to November 2024, focusing on therapeutic indications, was conducted. RESULTS: A total of 38% (n = 486 of 1281) of patients were diagnosed with MASLD F2 and F3 based on biopsy. However, only 39% and 56% of them met treatment eligibility criteria according to the Expert Panel Criteria and the American Association for the Study of Liver Diseases Practice Guidance, respectively. They included 45% of patients with early-stage fibrosis. False positive and false negative rates ranged from 23% to 41% and 44% to 60%, respectively, with area under the receiver-operating characteristic curve values below 0.60.These findings were validated in an external cohort. A two-step strategy, first selecting patients with Fibrosis-4 (FIB-4) =1.30, or with diabetes and overweight if FIB-4 <1.30, followed by a liver stiffness between 8 and 25 kPa, demonstrated higher positive (55%) and negative predictive values (77%) and higher area under the receiver-operating characteristic curve (0.67).This approach successfully identified 74% of the target population. CONCLUSIONS: The diagnostic performance and reliability of the proposed noninvasive criteria for initiating resmetirom treatment were suboptimal. About the half of patients with indication would not receive treatment under these criteria. A new strategy, using FIB-4, the presence of diabetes and overweight, and liver stiffness improved the identification of MASLD patients with F2 and F3.

Filiaciones:
Olveira A:
 Digestive Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain

Crespo J:
 Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Santander, Spain

Ibañez-Samaniego L:
 Liver Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain

Gallego-Durán R:
 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain

 SeLiver Group, Instituto de Biomedicina de Sevilla, Sevilla, Spain

Calleja JL:
 Digestive Department, Hospital Universitario Puerta de Hierro, Madrid, Spain

Aller R:
 Centro de Investigación de Endocrinología y Nutrición, Hospital Clínico Universitario de Valladolid, Universidad de Valladolid, Spain

Soria A:
 Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

Gómez-Camarero J:
 Digestive Department, Hospital Universitario de Burgos, Burgos, Spain

Martín-Mateos R:
 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain

 Digestive Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá, Madrid, Spain

Benlloch S:
 Digestive Department, Hospital Arnau de Vilanova, Universidad Cardenal Herrera-CEU Universities, Valencia, Spain

Pericàs JM:
 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain

 Liver Unit, Vall d'Hebron University Hospital Campus, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain

:
 Digestive Department, Hospital Germans Trias i Pujol, Badalona, Spain

Bernal-Monterde V:
 Digestive Department, Hospital Universitario Miguel Servet, IISAragon, Zaragoza, Spain

Diago M:
 Digestive Department, Hospital General Universitario de Valencia, Valencia, Spain

Turnes J:
 Digestive Department, Complejo Hospitalario Universitario de Pontevedra and IIS Galicia Sur, Pontevedra, Spain

Poca M:
 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain

 Digestive Department, Hospital de la Santa Creu i San Pau, Barcelona, Spain

Lo Iacono O:
 Digestive Department, Hospital Universitario Tajo, Aranjuez, Spain

Maya-Miles D:
 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain

 SeLiver Group, Instituto de Biomedicina de Sevilla, Sevilla, Spain

Escudero D:
 Digestive Department, Hospital Clínico Universitario de Valencia, Universitat de València, Valencia, Spain

Andrade RJ:
 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain

 Unidad de Gestión Clínica de Enfermedades Digestivas, Instituto de Investigación Biomédica de Málaga-IBIMA-Plataforma BIONAND, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Malaga, Spain

Rosales JM:
 Digestive Department, Hospital Costa del Sol, Marbella, Spain

Jorquera F:
 Servicio de Aparato Digestivo, Complejo Asistencial Universitario de León, IBIOMED, León, España

Fernández-Rodríguez C:
 Digestive Department, Hospital Universitario Fundación de Alcorcón, Universidad Rey Juan Carlos, Madrid, Spain

Hernández-Guerra M:
 Digestive Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

Romero-Gómez M:
 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain

 SeLiver Group, Instituto de Biomedicina de Sevilla, Sevilla, Spain

 Digestive Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain

 Universidad de Sevilla, Sevilla, Spain

Ampuero J:
 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain

 SeLiver Group, Instituto de Biomedicina de Sevilla, Sevilla, Spain

 Digestive Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain

 Universidad de Sevilla, Sevilla, Spain
ISSN: 15423565





Clinical Gastroenterology and Hepatology
Editorial
W. B. Saunders Co., Ltd., United States, Reino Unido
Tipo de documento: Article
Volumen: 24 Número: 4
Páginas: 1044-1054
WOS Id: 001724352500001
ID de PubMed: 40907848

MÉTRICAS